Evidence map›Paper›PMID 39839901›Full record

Trial reportWorld journal of gastroenterology2025

C-X-C chemokine receptor type 5

Zhen-Yu Xu, Zhong-Shang Dai, Guo-Zhong Gong, Min Zhang

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhen-Yu XuDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Zhong-Shang DaiDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Guo-Zhong GongDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Min ZhangInstitute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China. zhangmin001@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC-X-C chemokine receptor type 5 (CXCR5)

aimTo elucidate the relationship between CXCR5

methodsThis study enrolled 60 patients with hepatitis Be antigen (HBeAg)-positive CHB undergoing 48 weeks of peg-IFN-α treatment. Participants were assessed for eligibility based on criteria such as persistent HBsAg-positive status for at least six months, HBeAb-negative, hepatitis B virus DNA levels exceeding 2 × 10

resultsPatients with CHB exhibited significantly lower levels of circulating CXCR5

conclusionThe enhanced expression of CXCR5

Indexed as

Antiviral AgentsCD8-Positive T-LymphocytesHepatitis B, ChronicInterferon-alphaReceptors, CXCR5AdultB7-H1 AntigenDNA, ViralFemaleHepatitis B e AntigensHepatitis B virusHumansMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsAntiviral AgentsB7-H1 AntigenCD274 protein, humanCXCR5 protein, humanDNA, ViralHepatitis B e AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsReceptors, CXCR5Recombinant ProteinsChronic hepatitis BC-X-C chemokine receptor type 5Interleukin -21Pegylated interferon-alphaProgrammed death-ligand 1

Identifiers

PMID39839901
PMCPMC11684170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.